Real-world progression-free survival of first line afatinib patients with EGFR-mutant advanced lung adenocarcinoma: A multicentre study in Indonesia

Real-world progression-free survival of first line afatinib patients with EGFR-mutant advanced lung adenocarcinoma: A multicentre study in Indonesia

Introduction: Afatinib, a second-generation EGFR tyrosine kinase inhibitor (TKI), has demonstrated clinical benefit in EGFR-mutant non-small cell lung cancer (NSCLC) through clinical trials. However, real-world data, particularly in Southeast Asian populations, remain limited. This study aimed to ev...

Full description

Saved in:
Bibliographic Details
Main Authors: Noni Novisari Soeroso, Elisna Syahruddin, Chaliza Soliha, Laksmi Wulandari, Ana Rima Setijadi, Sabrina Ermayanti, Suryanti Dwi Pratiwi, Andreas Infianto, Novita Andayani, Sri Melati Munir, Avissena Dutha Pratama, Ida Ayu Jasminarti Dwi Kusumawardani, Haryati Haryati, Natalie Duyan, Muhammad Alfin Hanif, Darren Wan-Teck Lim
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Cancer Treatment and Research Communications
Subjects:
Real-world
Lung adenocarcinoma
EGFR mutation
Afatinib
Progression-free survival
Online Access:http://www.sciencedirect.com/science/article/pii/S2468294225001157
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items